Key result
Concurrent prescription of SSRIs and NSAIDs was associated with an increased risk of upper gastrointestinal bleeding (OR 2.93; 95% CI 2.25-3.82), but this was not substantially higher than use alone.
Why the study?
Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding compared to their use alone?
Population
11,261 cases with upper gastrointestinal bleeding and 53,156 controls matched by gender, age and general…
Comparison
Concurrent prescription of selective serotonin… vs Use of selective serotonin reuptake inhibitors…
Design
Case-control
Authors
Loading...
Concurrent SSRI-NSAID use shows no substantial additive bleeding risk; leaves open need for prospective confirmation.
Case-Control (n=64,417)
Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding compared to their use alone?
Odds Ratio: 2.93 (95% CI 2.25–3.82)
Concurrent use of SSRIs and NSAIDs does not substantially increase the risk of upper gastrointestinal bleeding beyond the risk associated with either drug class alone.
Tata et al. (2005) conducted a case-control in Upper gastrointestinal bleeding (n=64,417). Concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs vs. Use of either drug alone or no exposure was evaluated on Upper gastrointestinal bleeding (OR 2.93, 95% CI 2.25-3.82). Concurrent prescription of SSRIs and NSAIDs was associated with an increased risk of upper gastrointestinal bleeding (OR 2.93; 95% CI 2.25-3.82), but this was not substantially higher than use alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: